Merck (MRK) Cash from Operations (2009 - 2026)
Merck (MRK) posted quarterly Cash from Operations of 3918000000.0 for Q1 2026, up 56.72% YoY from 2500000000.0 in Q1 2025, and up 37.14% sequentially from 2857000000.0 in Q4 2025.
Merck (MRK) Cash from Operations (2009 - 2026) Analysis & Trends
Merck has disclosed Cash from Operations across 18 years of filings, most recently posting 3918000000.0 for Q1 2026.
- In Q1 2026, Cash from Operations rose 56.72% year-over-year to 3918000000.0; the TTM figure through Mar 2026 stood at 17890000000.0 (down 14.31% YoY), while the FY2025 annual figure was 16472000000.0, down 23.27% from the prior year.
- Cash from Operations grew to 3918000000.0 in Q1 2026, from 2857000000.0 in the prior quarter.
- Over the last five years, Cash from Operations for MRK reached as high as 9291000000.0 in Q3 2024 and fell as low as 246000000.0 in Q4 2023.
- The 5-year median for Cash from Operations is 3918000000.0 (2026), against an average of 4350529411.76.
- Annual changes were most pronounced in 2023 — Cash from Operations plunged 94.45% — and 2024, when it surged 1302.44%.
- A 5-year view of Cash from Operations shows it stood at 4430000000.0 in 2022, then sank by 94.45% to 246000000.0 in 2023, then surged by 1302.44% to 3450000000.0 in 2024, then retreated by 17.19% to 2857000000.0 in 2025, then soared by 37.14% to 3918000000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 3918000000.0, 2857000000.0, and 7822000000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 5.33 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 2.51 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 3.83 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 3.92 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 2.19 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 2.54 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 2.62 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 645.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.92 Bn |
| Mar 31, 2026 | 3.92 Bn |
| Dec 31, 2025 | 2.86 Bn |
| Dec 31, 2025 | 2.86 Bn |
| Sep 30, 2025 | 7.82 Bn |
| Sep 30, 2025 | 7.82 Bn |
| Jun 30, 2025 | 3.29 Bn |
| Jun 30, 2025 | 3.29 Bn |
| Mar 31, 2025 | 2.50 Bn |
| Mar 31, 2025 | 2.50 Bn |
| Dec 31, 2024 | 3.45 Bn |
| Dec 31, 2024 | 3.45 Bn |
| Sep 30, 2024 | 9.29 Bn |
| Sep 30, 2024 | 9.29 Bn |
| Jun 30, 2024 | 5.64 Bn |
| Jun 30, 2024 | 5.64 Bn |
| Mar 31, 2024 | 3.09 Bn |
| Mar 31, 2024 | 3.09 Bn |
| Dec 31, 2023 | 246.00 Mn |
| Dec 31, 2023 | 246.00 Mn |